Axera

Infections caused by susceptible microorganisms eg, lower resp tract including pneumonia (moderate to severe) & bronchitis, uncomplicated & complicated UTI including pyelonephritis, skin & skin structure, complicated intra-abdominal including peritonitis & biliary tract infections. Empiric therapy for febrile neutropenic patients. Septicemia.

IV/IM Adult & childn >40 kg Moderate to severe pneumonia 1-2 g every 12 hr for 10 days. Mild to moderate uncomplicated or complicated UTI including pyelonephritis &/or concurrent bacteremia 500 mg-1 g every 12 hr for 7-10 days. Severe uncomplicated or complicated UTIs including pyelonephritis &/or concurrent bacteremia 2 g every 12 hr for 10 days. Moderate to severe uncomplicated skin & skin structure infections 2 g every 12 hr for 10 days. Complicated intra-abdominal infections (combination w/ metronidazole) 2 g every 12 hr for 7-10 days. Empiric therapy for febrile neutropenic patients 2 g every 8 hr for 7 days or until neutropenia resolves. Very severe or life-threatening infections 2 g every 8 hr for 7-10 days; may require longer treatment for more severe infections. Childn ≤40 kg All infections 50 mg/kg/dose. Frequency & duration: Same as adult. Emperic therapy for febrile patients 50 mg/dose every 8 hr. Very severe or life-threatening infections 50 mg/dose every 8 hr for 7-10 days; may require longer treatment for more severe infections.

Hypersensitivity to cephalosporins or penicillin. Cross-hypersensitivity among β-lactam antibiotics. Discontinue if allergic reaction; symptoms of neurotoxicity or seizures occurs. Clostridium difficile-associated diarrhea. Serious adverse events, including life-threatening or fatal encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor & coma), myoclonus & seizures &/or renal failure may occur especially in patients w/ renal impairment. Patients at high risk of severe infection (including history of recent bone marrow transplantation, hypotension, underlying malignancy or severe or prolonged neutropenia). Overgrowth of non-susceptible organisms. Monitor prothrombin time. Long-term or repeated use. Renal or hepatic impairment.

Hypersensitivity reactions including eosinophilia, joint pain or inflammation, edema, facial edema, genital & anal pruritus, angioedema, shock, hypotension, SJS, erythema multiforme, TEN, exfoliative dermatitis; anaphylaxis; thrombocythemia, leukocytosis, granulocytosis, monocytosis, lymphocytopenia, basophilia, anemia, aplastic & hemolytic anemia, pancytopenia, epistaxis or hemorrhage; renal dysfunction, toxic nephropathy; vag candidiasis, menstrual irregularities; transient increase in γ-glutamyl transferase conc; increased serum bilirubin &/or LDH; decreased serum albumin &/or total protein; hepatic dysfunction including cholestasis; thrombophlebitis; malaise, fatigue, nightmares, vertigo, hyperactivity, nervousness or anxiety, agitation, hallucinations, insomnia, somnolence, weakness, hot flushes, alteration in color perception, confusion, hypertonia; chest pain, pleural effusion, pulmonary infiltrate, resp distress, cough, rhinitis; increased or decreased serum glucose conc.

Cephalosporins

J01DE01 - cefepime ; Belongs to the class of fourth generation cephalosporins. Used in the systemic treatment of infections.

Rx